



# SYGNIS AG

## Innovative Tools for DNA Amplification and Sequencing

Annual General Meeting, 20<sup>th</sup> June 2016

## Disclaimer

---

This document is intended for prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. This document also may contain projections and/or estimates about and descriptions of plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements. These statements are forward-looking and are subject to risks and uncertainties, many of which are beyond our control and are not to be regarded as guarantees of future events.

Actual results could differ materially depending on a number of factors, including the timing and effects of regulatory actions, the results of product tests, the Company's relative success developing and gaining market acceptance for any new products, and the effectiveness of patent protection.

There can be no guarantee regarding the results of the product tests or other on going studies with our products. There can be no guarantee that our products in development will be approved for marketing in a timely manner, if at all.

The Company disclaims any intent or obligation to update these forward-looking statements or the factors that may affect the Company's future results, performance or achievements, even if new information becomes available in the future.

# FY 2015 Highlights



## Main achievements for 2015

- Two product lines and six kits launched (TruePrime and SunScript)
- More than 14 distribution agreements signed
- Revenues grew to EUR 0.6 million (2014: EUR 0.4 million), in line with guidance
- Strong increase in product sales quarter by quarter (CAGR 01-12/2015 40.1%)
- Successful capital increase by rights offering and private placement with EUR 5.6 million raised
- Management team strengthened with new VP Marketing & Sales and new VP Finance & Administration
- Significant increase in marketing and sales activities.

## After period ended:

- Proposal to the AGM of a capital increase to acquire Expedeon and receiving some cash to finance the transaction.
- SYGNIS has moved Qiagen license agreement to non-exclusive

## 2015 Key Events

- **January 2015:** SYGNIS launched their first TruePrime™ kit targeting single cell WGA
- **February 2015:** SYGNIS launched their second TruePrime™ kit targeting WGA of regular amounts of DNA
- **March 2015:** GBC analyst launched a report with a share price target of EUR 4.05 (buy recommendation)
- **April 2015:**
  - SYGNIS launched their first SunScript™ kit, one step RT-qPCR
  - The company appointed Dr. Miguel Viribay as a VP of Marketing and Sales. He is person with a lot of expertise in the industry, coming from the sales area of the big players (ThermoFisher, Agilent)
- **June 2015:**
  - SYGNIS launched their third kit based in TruePrime™, RCA
  - Edison launched an update report highlighting that the company is fulfilling their product launching schedule
- **July 2015:** SYGNIS AGM approved all the topics in the agenda

## 2015 Key Events

---

- **July 2015:** SYGNIS appointed Mr. Sebastian Paul as VP of Finance and Administration. He is a finance person with a huge experience in German audit procedures (many years at E&Y)
- **September 2015:**
  - SYGNIS launched their second SunScript™ kit, RNaseH+ and RNaseH-
  - Edison launched an update with the commercial agreements signed by SYGNIS
- **November 2015:** GBC analyst launched a report with a target price of EUR 3.75 per share (buy recommendation)
- **December 2015:**
  - Edison launched an update with the capital increases details
  - SYGNIS closed successfully a capital increase of EUR 5.6M, with a share price of EUR 1.90 per share.

## 2015 Key Events

---

- **December 2015:**

- The Company conducts a capital increase with a contribution in kind as Genetrix convert their loan into equity with a share price of EUR 1.90 per share
- The Company launched their third SunScript™ kit, one step RT-PCR kit
- The Company has fulfilled its launched scheduled presented at the end of 2014
- After the increase of capital the new free float is approx. 50%
- The Company has signed 14 non exclusive distribution agreements with different commercial distributors, experts in the genomic field, all over the world
- Just before the end of 2015, the Company signed two new distribution agreements with two U.S. companies, Mayflower and Lucigen, starting with their commercialization in U.S.A

## 2015 Capital Increase

- The Company has launched all the scheduled products on time during 2015
- In parallel the Company has signed 14 distribution agreements to cover EU, Asia and U.S.A with distributors
- The main market for SYGNIS products are the U.S., where the Company didn't have any distributor until end of 2015
- In a first step, the Company covered the EU, however, the second main step for SYGNIS was to enter into U.S. market with its products
- Aiming this, the Company has done a capital increase to obtain cash to expand their activities in U.S.A, the key market for their products
- The Company has been using SEDA during 2015 in a very low range, only EUR 438,000 were raised through this financial tool
- As the market conditions were not very good to use SEDA to get more cash for their commercial activities in the U.S. (Greek crisis, Chinese crisis etc. and low volume in the markets) the Company decided to go for a capital increase at the end of the year
- The capital increase was successfully closed, obtaining EUR 5.6 M of gross proceeds plus a contribution in kind from Genetrix (compensation of a loan)

## 2016 Performance Overview

---

- During Q1 the revenues of kits are maintaining their growth tendency; CACO-2 sales are decreasing
- May 2016: The Company announced the acquisition of Expedeon Ltd., a UK based company, focused in the proteomic field, with their own sales force covering the main markets and with positive EBITDA
- The transaction will be done through a capital increase of up to 20 M shares, a part of them will be used to pay Expedeon shareholders (contribution in kind) and part of it to get up to EUR 5M in cash. This cash will be used partially to pay 6% of the transaction to Expedeon shareholders (EUR 1.7M), EUR 1.2M to pay the transaction and capital increase cost and the rest as a cash buffer for the company.
- The share price for the capital increase has not been decided yet
- Current market valuation of the company: approx. EUR 25M



## 2016 Performance Overview

---

- As Qiagen has not fulfilled the minimum sales volume established in their license agreement for 2015, SYGNIS has moved their license agreement to a non-exclusive situation. Due to this, SYGNIS is analyzing the possibility to launch products or other license agreements based on SensiPhi® (the enzyme licenced to Qiagen in 2012) during the next months.
- In June 2016, SYGNIS AG announced a new tool for the detection and amplification of cell-free DNA in blood, a critical step for the early diagnosis and prevention of tumors. The new tool is based on SYGNIS' TruePrime™ technology and enables the early detection of cancer using a blood sample instead of tissue biopsies

# Company Profile: SYGNIS

## **SYGNIS develops and markets innovative tools for DNA amplification and sequencing**

### **SYGNIS Product Business:**

Focus on the development and commercialization of own product portfolio

Two product lines launched:

- TruePrime™ for whole genome amplification
- SunScript™ Reverse Transcriptase for translating RNA into DNA

Commercialization strategy: Direct sales, distribution network, OEM agreements

### **SYGNIS Licensing Business:**

SensiPhi™/Qualiphi™ core technology licensed to QIAGEN

Double Switch technology components licensed to SYSTASY

Double Switch non-exclusive license to Thermo-Fisher

Caco-2 non-exclusive license agreements with several third parties

Frankfurt Stock Exchange (Prime Standard): Ticker: LIO1 (Xetra) LIOG1.DE (Reuters Instrument Code)

Two facilities, Madrid-Spain and Heidelberg, Germany, 21 people

# Genetic Profile: DNA

SYGNIS develops and markets innovative tools for DNA amplification and sequencing.



The genetic profile of a person is in the DNA of this person. So we need to study the DNA to obtain this information.

## Steps that needs to be done to study the DNA

The genetic profile of a person is in the DNA of this person.  
So we need to study the DNA to obtain this information.




### Limited sample

Clinical sample (e.g. biopsies)

Irretrievable sample

Stored DNA

Analysis with need of higher amounts of DNA (e.g. NGS)



### TruePrime® product line

Primer-free Whole Genome Amplification from rare samples down to single cells using proprietary TruePrime® technology




### Enough DNA

for an almost unlimited number of tests and analysis

- ➔ Companion diagnostics
- ➔ Next Generation Sequencing
- ➔ SNP genotyping
- ➔ Clinical studies
- ➔ Patient genotyping

...

# SYGNIS Covers Critical Value Steps in the NGS Workflows



# SYGNIS: TruePrime™ Product Line

## The Revolution in Whole Genome Amplification

### Technology:

Combination of **TthPrimPol Primase** with **Phi29 Polymerase**

**TthPrimPol** to synthesize primers during reaction process

**Phi29** to perform strand displacement and polymerization of DNA molecules

### Available products:

TruePrime™ Single Cell WGA Kit → launched January 2015

True Prime™ WGA Kit → launched February 2015


TruePrime™ RCA kit → launched June 2015



### Competitive advantages and customer benefits:

- No synthetic primers needed - complete absence of common artifacts linked to the use of oligonucleotides
- Reduced amplification bias in genome coverage
- High reliability
- Insensitive to external DNA (no amplification of potential DNA contamination)
- Exquisite reproducibility when DNA is amplified
- Superior sensitivity
- Easy of use
- Works well with all commonly used NGS platforms such as Illumina and Ion Torrent.

# SYGNIS: TruePrime™ is Insensitive to External DNA Contaminations



➔ **Input:** 1 pg of denatured human gDNA plus non-denatured yeast gDNA (“contaminant DNA”) added in 1000-fold excess (1 ng) to the amplification mix

# SYGNIS: Chromosome 3 Coverage (12 Million Read Out Pairs)


Control: Non-amplified DNA

TruePrime™

Competitor R

Competitor G

Random primers



# SYGNIS: SunScript™ Product Line Reverse Transcriptase (RT) for ultra-fast Translation of RNA into DNA

## Technology :

- Novel proprietary engineered reverse transcriptase
- Derived from the well characterized HIV-1
- One of the most thermostable and fastest enzyme commercially available today

## Available:

- SunScript™ Reverse Transcriptase —————→ launched April 2015
- SunScript™ One Step Reverse Transcriptase-PCR Kit —————→ launched September 2015
- SunScript™ One Step RT-qPCR Kit —————→ launched December 2015



## Competitive advantages and customer benefits:

- High thermostability: Active up to 85° C to resolve even the most complex RNA structures
- High reaction speed of > 30 bases per second
- High yields of first strand cDNA
- Complete reverse transcription of very long RNA molecules
- High sensitivity
- Yields highly consistent and reproducible results



## Licensed Products: SensiPhi®

SensiPhi® licensed to QIAGEN the world leading supplier of sample and assay technologies.

SYGNIS

Supplies  
SensiPhi®



Product  
revenues  
Royalties



SensiPhi® is an essential part of  
QIAGEN's REPLI-g® Kits



QIAGEN plans to replace standard Phi-29 polymerase  
in their current amplification kits by SensiPhi®.

QIAGEN launched the first kits using SensiPhi® beginning 2014.


QIAGEN creates standards and addresses life science laboratories all over the world.

## Pipeline: Double Switch


**Fundamental technology for the detection of protein-protein interactions based on the full-length or split TEV protease.**

- Strong, granted IP in Europe and the U.S.
- Enables construction of a broad range of assays of interest to basic scientists and the pharma industry
- Big pharma companies that want to implement innovative screening platforms to look for new therapeutic targets, and drug screening service providers are the companies that could be interested in this screening platform
- Patent transfer agreement for some patents linked to the Double Switch project with SYSTASY Bioscience GmbH signed in May
- Non Exclusive license to ThermoFisher in July 2015

# Product Launch Map for 2015



# Proprietary Product Launch Map for 2016



# SYGNIS + Expedeon: Innovation Strength Meets Sales Power



# Molecular Biology Market

## Genomics (\$22B)

DNA

RNA

### Key applications:

Sequencing

Microarray technology

PCR, DNA amplification

Nucleic acid extraction and purification

SYGNIS

## Proteomics (\$17.2B)

Protein

### Key Applications:

Protein Microarray

Mass Spectrometry

NMR Spectroscopy

Chromatography

Electrophoresis

Surface Plasmon Resonance

Protein Fractionation

X-ray Crystallography

Immunoassay

Expedeon

# Company Profile: Expedeon Holdings Ltd.

**Expedeon develops innovative products in the electrophoresis and proteomics market: Reagents and tools company in the life sciences environment**

## **Expedeon Portrait:**

Cambridge University spin-out

Private company

Revenues above EUR 2.5 M (2015)

Profitable

Strong revenue and EBITDA growth

Three locations (Cambridge, UK; San Diego, U.S.A and Singapore) with 25 employees

## **Expedeon Core Products:**

RunBlue      Electrophoresis

Gelfree      Fractionation

Nvoy      Solubility

Versawave      Quantitation

Amintra      Purification

## **Core Technologies:**

RunBlue      Photo polymerization technology/composite gel technology

InstantBlue      Detergent knock out technology

Nvoy      Protein chaperoning technology

Versawave      Micro-cuvette technology (pipette tips)

Established sales force and distribution network in EU, U.S. and Asia

# FY 2015 Highlights Expedeon Holdings Ltd.



## Achievements 2015:

- New product range launched
- OEM deal signed with major Chinese player
- Revenues up to EUR 2.5 million in 2015
- Projected revenue: >EUR 3.5 – 3.6 million in 2016
- Growth momentum: 5 years CAGR >20%
- High gross margin: 77%
- Improved EBITDA (13%)
- Strong sales performance: 55% direct sales
- Significant U.S. presence: 33 % of total sales



# Expedeon's Strength: Strong Direct Sales Force

## Sales Channels

### Direct Sales (55%)

- UK, Germany, France, U.S.
- Higher margins
- Customer feedback
- End-user database → marketing

### Distribution (35%)

- Local distributors: Europe, Far East
- Global distributors (Fisher, VWR, Sigma)
- Wider reach


### OEM (10%)

- Global reach
- Lower margins
- Economies of scale

## Marketing Approach



# Expedeon: Sales Strategy



■ North America      ■ UK  
■ Europe              ■ Rest of the world

## Direct sales force:

Focus sales reps in territories with physical presence:

- **UK:** Cambridge, Oxford, London, Manchester, Dundee – Edinburgh
- **U.S.:** San Diego/LA, San Francisco, Boston, Maryland (NIH)

## OEM deal: SIGMA

- 3-year relationship, CAGR growing stronger every year
- Blend of distribution and OEM precast gels range
- OEM InstantBlue distribution


# Expedeon: Access to the Chinese Market



## Recent OEM deal: TANON (Chinese partner, signed in December 2015)

- New relationship with strong commitment of \$1M for 2016
- Projected growth of 50% for first 2 years
- Chinese market leader for Gel-doc systems
- Wide existing user base
- Perfect cross-selling opportunities
- Access to Chinese market with a major national player
- Opportunity to role out additional product lines

## Expedeon Current Shareholder Structure (15,718,889 shares)



■ Bill Alpenfels

■ Joe Fernandez

■ Heikki Lanckriet

■ Sante Health Ventures

■ Daniel Jones

■ Other

# Creating a Major Life Sciences Reagents & Tools Organization covering Genomics and Proteomics with a Dedicated Sales Force



## Advantages for SYGNIS:

- Acquires efficient sales force that can rapidly promote SYGNIS products and accelerate sales growth
- Expedeon CEO is scientist with strong industry expertise. Profile highly complementary to SYGNIS CEO
- Synergies in sales, R&D, manufacturing and logistics
- Broadened product and technology portfolio, entry into proteomics
- Expedeon presence in U.S. and Asia will allow to enter these markets much faster

## Advantages for Expedeon:

- Access to the capital markets
- SYGNIS CEO with strong public company and financing expertise
- Access to new innovative technology, expand product portfolio to genomics
- Increased ability to implement growth strategy and become a key player in the reagents/consumables space



**Combination = Strong near-term growth potential and critical mass**

# Outlook 2016: SYGNIS and Expedeon

SYGNIS	Combination	Expedeon
Molecular diagnostics and DNA tools	Covering genomics and proteomics markets and know how	Proteomics-focused product and technology portfolio
	Increased critical mass and international visibility	
<b>Revenues:</b> EUR 1.2 – 1.5 M <b>Operational costs:</b> Less than 2015 level	<b>Revenues:</b> EUR 4.6 – 5.1 M <b>Operational costs:</b> Less than merged 2015 level	<b>Revenues:</b> EUR 3.5 – 3.6 M <b>Operational costs:</b> Less than 2015 level
	Become a significant player in the reagents and tools business	

# Transaction Summary



## SYGNIS acquires Expedeon:

- Planned capital increase by way of a rights offering of up to approximately 20.5 million shares
- New shares not subscribed will be offered to Expedeon shareholders as contribution in kind in exchange for Expedeon shares (15,718,889 shares)
- Expected proceeds of up to EUR 5 million to cover additional EUR 1.7 million cash payment to Expedeon shareholders and transaction- and integration-related expenses and working capital
- Lock-up agreement for Expedeon and major SYGNIS shareholders

## Timeline:

- Transaction official approval:  
20 June 2016, SYGNIS AGM

## Details on Lock-up Agreements

- For Expedeon Management (Heikki Lanckriet, Daniel Jones, and William Alpenfells), 20% released at month 12, further 20% released every 3 months, i.e. full release after 2 years.
- For Expedeon shareholders over 3%, Expedeon Directors (Joe Fernandez, Trevor Jarman, Tim McCarthy, Sarah Roth, Sante Health Ventures, Frans De Busschere, and Brenn-Cogen trust), 20% released at month 6, 20% released every 4 months, i.e. full release after 1.5 years.
- For SYGNIS shareholders over 3% (Genetrix SL, dievini Hopp Biotech Holding, and Veriphi SL) 25% released at month 6, 25% released each quarter, i.e. full release within 1.5 years.
- And, for all other Expedeon shareholders below 3%, 20% released on completion, further 20% released every 3 months, i.e. full release after 1 year.



# Valuation Expedeon


## Valuation factors

- Net cash value: discounted free cash flows for the detailed forecast period (2016 to 2025) and discounted going concern value
- Discount factor of 12% (SYGNIS discount factor)
- For going concern (residual) value long-term growth rate of 3% applied
- Calculated value of Expedeon £ 47.2 million or EUR 61.5 million (FX rate 0.77)
- Expedeon number of shares 15,718,889
- Calculated value per share: EUR 3.91

## PURCHASE PRICE

15.7 million SYGNIS shares (agreed price EUR 1.80) and EUR 1.7 million in cash

# Merged Entity: Organization Chart



# New Management Board



## Pilar de la Huerta, MBA – Co-CEO/CFO

Pilar became Genetrix's CEO in 2010 as result of her successes in executive roles in biotech companies over the last 15 years. She joined Genetrix from Viamed Salud where she was responsible for R&D and New Business and was appointed as CEO of Araclon, S.L where at the end of 2006 they closed a financial round raising €8M in private equity. Previously she assumed various responsibilities within the Zeltia Group (largest biotech group in Spain since 1998) where under her leadership as CFO she led a successful IPO raising €230M (the highest amount by a European biotech since 2000). In addition, her key contribution as CEO of Noscira, Zeltia Subsidiary, was closing a private placement up to €16M in 2004. Pilar became SYGNIS CEO following the reversed merger with SYGNIS and X-pol, a subsidiary of Genetrix, in 2012. Pilar holds a Bachelor's Degree in Business and Administration by the UCM and has completed the IESE's Advanced Management Program (AMP) and Program for Management Development (PMD) courses in the Navarra University.



## Heikki Lanckriet, PhD – Co-CEO/CSO

Heikki Lanckriet (PhD) has developed broad expertise and commercial experience in the Life Science Tools and Reagents area. In 2003, whilst at Cambridge University, Heikki co-founded Expedeon. As the company developed he accumulated a deep knowledge of the many facets of business by evolving through the roles of COO, CSO and CEO which is the position he currently holds in the company. His entrepreneurial spirit and commercial pragmatism are at the centre of the Expedeon's success. Heikki holds a Bachelor's and Master's degree in Biochemical Engineering from the University of Ghent, Belgium and a PhD in Biochemical Engineering from the University of Cambridge, UK. He has published papers in high impact peer-reviewed international scientific journals and is named inventor on a multitude of patents.

# SYGNIS Supervisory Board following the Expedeon Acquisition



**Cristina  
Garmendia**  
PhD  
Chairwoman



**Tim  
McCarthy**  
(new following  
Expedeon M&A)



**Mr. Joseph  
Fernandez**



**Franz Wilhelm  
Hopp**  
PhD



**Trevor  
Jarman**  
PhD  
(new following  
Expedeon M&A)




**María Jesús  
Sabatés Mas**

# Summary



- Successful launching of two new product lines and six kits
- Broad distribution network with global partners cover most important geographical markets
- New products to be launched during 2016, with special focus to the cell free DNA WGA kit (clinical market)
- Appointment of Dr. Miguel-Antonio Viribay as Vice President Sales & Marketing to boost future sales especially in Europe and the U.S.
- Appointment of Mr. Sebastian Paul as Vice President of Finance and administration
- Solid financial situation
- Acquisition of Expedeon will reinforce the commercial strategy of SYGNIS with their own sales force in the main markets, will increase and complement the portfolio and will optimize the cost structure of the company, moving the combo to reach profitability in a short term period.

# Report on Consolidated Financial Statements 2015



## Key Considerations Annual Accounts 2015

---

- Revenues in line with guidance and increased to EUR 0.6 million (2014: EUR 0.4 million)
- Recurring operating expenses at EUR 3.8 million (2014: EUR 3.6 million)
- Operating loss before one-off items mostly unchanged at EUR 3.2 million
- Oversubscribed capital increase with proceeds of EUR 5.6 million in December 2015

## Shortened profit & loss statement SYGNIS AG (HGB)

(in EUR thousand)

	2015	2014	Change in %
Revenues	45	0	—
Other operating income	982	85	> 100.0
Personnel costs	-9	-384	-97.7
Other operating expenses	-2,527	-1,388	82.1
Taxes	16	0	—
<b>Net result</b>	<b>-1,493</b>	<b>-1,686</b>	<b>-11.4</b>



## Shortened balance sheet SYGNIS AG (HGB)

Assets (in EUR thousand)	31.12.2015	31.12.2014	Change in %
Shares in affiliated companies	45	0	–
Other assets	982	85	> 100.0
Cash and cash equivalents	-9	-384	-97.7
<b>Total assets</b>	<b>-1,493</b>	<b>-1,686</b>	<b>-11.4</b>

### Equity and liabilities (in EUR thousand)


Equity and cash deposit from capital increase	38,636	33,354	15.8
Provisions	519	370	40.3
Liabilities to affiliated companies	7	703	-99.0
Other liabilities	232	153	51.6
<b>Total assets</b>	<b>39,394</b>	<b>34,580</b>	<b>13.9</b>

## Shortened consolidated profit & loss statement (IFRS)

(in € thousand)	2015	2014	Change in %
Revenues	555	392	41.6
Costs of goods sold	-27	0	—
Selling & administrative expenses	-2,387	-1,935	23.4
Research & development expenses	-1,258	-1,413	-11.0
Other operating income	52	31	67.7
Impairment losses	-128	-283	< -100.0
<b>EBIT before one-off items</b>	<b>-3,193</b>	<b>-3,208</b>	<b>-0.5</b>
Expenses from one-off items	-670	0	—
<b>EBIT after one-off items</b>	<b>-3,863</b>	<b>-3,208</b>	<b>20.4</b>
Financial result	-177	-137	29.2
<b>Result before taxes</b>	<b>-4,040</b>	<b>3,345</b>	<b>20.8</b>
<b>Net results</b>	<b>-4,011</b>	<b>-3,480</b>	<b>15.3</b>

## Shortened consolidated profit & loss statement (IFRS)

**Group Profit & Loss Statement (IFRS) 2015 and 2014 (kEUR)**



## Shortened consolidated balance sheet (IFRS)

Assets (in € thousand)	31.12.2015	31.12.2014	Change in %
Intangible assets	1,826	1,678	8.8
Goodwill	5,942	5,942	0.0
Deferred tax assets	420	615	-31.7
Other non-current assets	136	184	-26.1
Cash and cash equivalents	4,557	3,764	21.1
Other current assets	1,152	354	> 100.0
<b>Total assets</b>	<b>14,033</b>	<b>12,537</b>	<b>11.9</b>

### Equity and liabilities (in € thousand)

Equity	10,413	8,342	24.8
Non-current financial liabilities	1,913	2,890	-33.8
Other liabilities	1,707	1,305	30.8
<b>Total assets</b>	<b>14,033</b>	<b>12,537</b>	<b>11.9</b>

## Shortened consolidated statements of cash flows (IFRS)


(in € thousand)	2015	2014	Change in %
Cash flow from operating activities	-3,185	-3,579	6.6
Cash flow from investing activities	-530	-621	-14.7
Cash flow from financing activities	4,741	5,439	-12.8

## Shortened Q1 consolidated P&L Q1 2016 (IFRS)

(in € thousand)	Q1 2016	Q1 2015	Change in %
Revenue	91	76	19.7
Costs of goods sold	-12	0	—
Selling & administrative expenses	-456	-503	-9.3
Research & development expenses	-318	-307	3.6
Other operating income	23	13	76.9
<b>EBIT</b>	<b>-672</b>	<b>-721</b>	<b>-6.8</b>
Financial result	-7	-26	-73.1
<b>Result before taxes</b>	<b>-679</b>	<b>-747</b>	<b>-9.1</b>
<b>Net results</b>	<b>-677</b>	<b>-735</b>	<b>-7.9</b>

## Shortened Q1 consolidated P&L Q1 2016 (IFRS)

Group Profit & Loss Statement Q1 2016 and 2015 (kEUR)



## AGM Agenda Items

---

1. Presentation of the annual accounts and consolidated financial statements, the management report and the Group management report and the report of the Supervisory Board, each for the fiscal year 2015
2. Discharge of the members of the Supervisory Board for the fiscal year 2015
3. Discharge of the members of the Management Board for the fiscal year 2015
4. Election of Supervisory Board Members
5. Election of the auditor for the financial year 2016
6. Resolution on the capital increase against contributions
7. Resolution on the cancellation of the remaining existing authorized capital and creation of a new authorized capital; authorization of the Management Board to exclude subscription rights of shareholders with the consent of the Supervisory Board
8. Resolution on the creation of a further new authorized capital; authorization of the Management Board to exclude subscription rights of shareholders with the consent of the Supervisory Board
9. Cancellation of conditional capital II and III
10. Cancellation of authorization to issue convertible bonds (with exclusion of subscription rights) and conditional capital V and creation of a new authorization to issue convertible bonds (with exclusion of subscription rights) and conditional capital V capital



## Overall Summary

- Six products successfully launched to the market in 2015
- Successful capital increase in December 2015
- Growing revenues from product sales
- SYGNIS' strategic position to be further improved by Expedeon acquisition
- Positive impact for revenue and result expected



**Therefore, please vote according to AGM agenda and support our strategy!**

# Thank you for your Attention.

**For more information, please contact:**

## **SYGNIS AG**

Pilar de la Huerta, CEO/CFO



Email: [pdelahuerta@sygnis.com](mailto:pdelahuerta@sygnis.com)



Phone: +34 91 192 36 50